24/7 Market News Snapshot 04 March, 2025 – CryoPort, Inc. Common Stock (NASDAQ:CYRX)

March 4, 2025

DENVER, Colo., 04 March, 2025 (247marketnews.com) – (NASDAQ:CYRX) are discussed in this article.
CryoPort, Inc., a prominent provider of supply chain solutions for the life sciences sector, has experienced significant momentum in its stock performance, opening at $4.75 and surging 14.49% to reach $5.49. This bullish trend is underscored by a trading volume of 960,540 shares, indicating heightened investor interest and engagement. As traders closely monitor key resistance levels near recent highs and support established at the opening price, the positive trajectory of CryoPort’s stock reflects its strengthening presence in the biotechnology market.

In conjunction with its stock performance, CryoPort has reported impressive fiscal results for the year ending December 31, 2024. The company achieved total revenues of $228.4 million, aligning well with projected guidance, while notably reporting a 20% year-over-year growth in revenue from the commercial Cell & Gene Therapy segment, which totaled $26 million. This increase highlights CryoPort’s dedication to facilitating innovative therapies that significantly impact patient care.

Further demonstrating its market strength, CryoPort supported a record 701 global clinical trials by year-end, which is an increase of 26 trials from the previous year. CEO Jerrell Shelton expressed pride in the results, particularly the performance of the Life Sciences Services division, which experienced a 6.6% year-over-year revenue rise fueled by strong growth in BioStorage/BioServices. Q4 2024 saw the company reach a gross margin of 45.8%, a significant improvement from 40.6% the prior year, reflecting effective cost management.

As it looks ahead, CryoPort projects full-year revenue guidance of $240 million to $250 million for 2025, aiming to enhance its market position through new service rollouts and strategic partnerships. With a focus on operational excellence, CryoPort is well-positioned to support advancing medical innovations and improve patient outcomes globally.

Related news for (CYRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.